Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EPS (Basic) (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed EPS (Basic) for 10 consecutive years, with $0.2 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 128.99% year-over-year to $0.2, compared with a TTM value of $1.4 through Dec 2025, up 161.95%, and an annual FY2025 reading of $1.4, up 161.4% over the prior year.
  • EPS (Basic) was $0.2 for Q4 2025 at Zevra Therapeutics, up from -$0.01 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.26 in Q2 2025 and bottomed at -$2.49 in Q1 2021.
  • Average EPS (Basic) over 5 years is -$0.28, with a median of -$0.26 recorded in 2022.
  • The sharpest move saw EPS (Basic) crashed 1100.0% in 2022, then skyrocketed 362.5% in 2025.
  • Year by year, EPS (Basic) stood at $0.05 in 2021, then tumbled by 620.0% to -$0.26 in 2022, then crashed by 107.69% to -$0.54 in 2023, then fell by 27.78% to -$0.69 in 2024, then surged by 128.99% to $0.2 in 2025.
  • Business Quant data shows EPS (Basic) for ZVRA at $0.2 in Q4 2025, -$0.01 in Q3 2025, and $1.26 in Q2 2025.